TEZSPIRE met both co-primary endpoints in the Phase III …
6 days ago · CRSwNP is a complex inflammatory disorder, characterized by persistent inflammation of the nasal mucosa accompanied by benign growths, called nasal polyps. 6,7 Nasal polyps can block nasal passages and lead to breathing problems, difficulty in sense of smell, nasal discharge, facial pain, sleep disturbance and other adverse effects on quality ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL …
5 days ago · CRSwNP is a complex inflammatory disorder characterized by persistent inflammation of the nasal mucosa accompanied by benign growths, called nasal polyps. 2,3 Nasal polyps can block nasal passages and lead to breathing problems, difficulty in sense of smell, nasal discharge, facial pain, sleep disturbance and other adverse effects on quality of ...
Tezspire Meets Co-primary Endpoints in Phase 3 WAYPOINT Trial
3 days ago · November 11, 2024. A Phase III trial, WAYPOINT, has yielded positive results for AstraZeneca and Amgen’s TEZSPIRE (tezepelumab) in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The randomized, double-blind trial demonstrated that TEZSPIRE significantly reduced nasal polyp size and nasal congestion compared to a placebo in adults ...
Tezspire Reduces Nasal Congestion and Polyp Size in Chronic …
2 days ago · November 11, 2024. Full results from the trial will be presented at an upcoming medical meeting. Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and nasal congestion in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). Tezepelumab is a human monoclonal antibody ...
Dupilumab in CRSwNP Gave Patients Significantly More Symptom …
Nov 4, 2024 · Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to study findings published in Annals of Allergy, Asthma & Immunology.
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal …
Oct 14, 2024 · GSK. On Monday, GSK plc (NYSE: GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with...
REAL-WORLD OUTCOMES FOLLOWING BIOLOGIC INITIATION IN …
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often have persistent symptoms and reduced health-related quality of life despite treatment with intranasal corticosteroids. Three biologic therapies are currently approved for CRSwNP in the …
GSK Announces Positive Phase III Results from ANCHOR Trials for ...
14 October 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with CRSwNP.
Dupixent receives FDA approval as first CRSwNP treatment
Sep 16, 2024 · The US Food and Drug Administration (FDA) has expanded the approval of Dupixent (dupilumab) to include adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
FDA Approves Dupilumab for Adolescents with Chronic …
Sep 13, 2024 · The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as an add-on maintenance therapy for individuals aged 12 - 17 years with chronic rhinosinusitis with nasal polyposis (CRSwNP). 1.